Working... Menu

Platelet Transfusion in HBV-related acute-on Chronic Liver Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03713489
Recruitment Status : Recruiting
First Posted : October 19, 2018
Last Update Posted : October 22, 2018
Information provided by (Responsible Party):
Jinjun Chen, Nanfang Hospital of Southern Medical University

Brief Summary:
Acute-on-chronic liver failure (ACLF) is a syndrome that has recently been recognized as encompassing acute deterioration of liver function in patients with pre-existing chronic liver disease. It is associated with multi-organ failure and a high risk of short-term mortality. Thrombocytopenia is common in ACLF. In addition, the function of platelet is also compromised according to our previous data. The aim of this study is to explore whether platelet transfusion could reduce the short-term mortality rate of HBV-related ACLF. This is a single center, open labeled randomized controlled study. There are two arms. Subjects who is assigned to platelet transfusion group will receive both platelet transfusion (9 times/4 weeks, 1 unit each time) and standard medical treatment. While those in standard medical treatment group will receive standard medical treatment only. The major endpoint is 28-day transplant-free mortality rate.

Condition or disease Intervention/treatment Phase
Acute-On-Chronic Liver Failure Procedure: platelet Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Platelet Transfusion in HBV-related acute-on Chronic Liver Failure: a Randomized Controlled Study
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : September 30, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Platelet transfusion group
Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
Procedure: platelet
Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.

No Intervention: standard medical treatment group
standard medical treatment

Primary Outcome Measures :
  1. 28-day transplant-free mortality [ Time Frame: 28 days ]
    whether participant died or not without liver transplantation

Secondary Outcome Measures :
  1. transplant-free survival time [ Time Frame: 90 days ]
    survival time without transplation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-60 years old
  • Diagnosed with acute-on-chronic liver failure (grade-2) according to EASL-CLIF criteria and grading system.
  • Chronic hepatitis B infection.
  • ADP inhibition rate ≥70%.

Exclusion Criteria:

  • Combined with chronic liver disease other than chronic HBV infection.
  • Previous decompensation.
  • Intracranial hemorrhage proved by radiological methods, symptoms and physical signs.
  • Under anti-platelet or anticoagulants therapy within 4 weeks.
  • Esophageal variceal bleeding within 1 week.
  • Platelets transfusion within 1 week.
  • Hepatocellular carcinoma or other types of malignancies.
  • Pregnancy or breastfeeding.
  • Severe chronic extra-hepatic disease.
  • Comined with situations that researchers considered not suitable for inclusion
  • Refusal to sign the informed consent form.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03713489

Layout table for location contacts
Contact: Jinjun Chen +8618588531001
Contact: Tingting Qi +8615521287260

Layout table for location information
China, Guangdong
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University Recruiting
Guangzhou, Guangdong, China, 510515
Contact: Jinjun Chen    86-18588531001   
Contact: Tingting Qi    +8615521287260   
Sponsors and Collaborators
Nanfang Hospital of Southern Medical University

Layout table for additonal information
Responsible Party: Jinjun Chen, Associate Director, Nanfang Hospital of Southern Medical University Identifier: NCT03713489     History of Changes
Other Study ID Numbers: 008
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: October 22, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jinjun Chen, Nanfang Hospital of Southern Medical University:
acute-on-chronic liver failure
Hepatitis B

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Failure
Hepatic Insufficiency
End Stage Liver Disease
Acute-On-Chronic Liver Failure
Liver Diseases
Digestive System Diseases
Liver Failure, Acute